Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AddLife ABADDLF 88 EV-to-EBITDA is 23.81 as of Aug. 04, 2026, which is 26% below its 10-year median of 32.10. GuruFocus rates ADDLF with a GF Score™ of 88/100 and a GF Value™ of $15.15. The stock has 5 warning signs investors should review. Among 512 Medical Devices & Instruments companies, AddLife AB ranks worse than 73.63% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AddLife AB's enterprise value is $2,601 Mil.
AddLife AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $109 Mil. Therefore, AddLife AB's EV-to-EBITDA for today is 23.81.
The historical rank and industry rank for AddLife AB's EV-to-EBITDA or its related term are showing as below:
ADDLF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 19.7 Med: 32.1 Max: 53.96
Current: 23.29
During the past 13 years, the highest EV-to-EBITDA of AddLife AB was 53.96. The lowest was 19.70. And the median was 32.10.
ADDLF's EV-to-EBITDA is ranked worse than 73.63% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.44
vs ADDLF: 23.29
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AddLife AB's share price for today is $15.75.
AddLife AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.521.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for AddLife AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, AddLife AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AddLife AB EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AddLife AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where AddLife AB's EV-to-EBITDA falls into.
AddLife AB's current Enterprise Value is $2,601 Mil.
AddLife AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $109 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AddLife AB (ADDLF) has a EV-to-EBITDA of 23.81 as of Aug. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AddLife AB. This is 26% below median its historical median of 32.10. Over the past decade, AddLife AB's EV-to-EBITDA has ranged from 19.70 to 53.96. According to the industry distribution chart, AddLife AB ranks #377 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 73.6%.
Is AddLife AB's EV-to-EBITDA too high?
AddLife AB's current EV-to-EBITDA of 23.81 is 26% below median its 10-year median of 32.10. Over the past 10 years, this metric has ranged from a low of 19.70 to a high of 53.96. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.44. AddLife AB's value of 23.81 is 64.9% above this industry median. Based on the distribution chart, AddLife AB ranks #377 out of 512 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, AddLife AB has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does AddLife AB's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, AddLife AB ranks #377 out of 512 companies for EV-to-EBITDA. This places AddLife AB in the lower half of its industry. The industry median EV-to-EBITDA is 14.44. AddLife AB's value of 23.81 is 64.9% above this benchmark. Historically, AddLife AB's own EV-to-EBITDA has ranged from 19.70 to 53.96 over the past decade. While the company's 10-year median is 32.10 vs. the industry median of 14.44, AddLife AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.44, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AddLife AB's current EV-to-EBITDA of 23.81 is 64.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AddLife AB. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AddLife AB's current EV-to-EBITDA is 23.81, which is 26% below median its own 10-year median of 32.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AddLife AB stock overvalued right now?
AddLife AB (ADDLF) has a current EV-to-EBITDA of 23.81. The stock's GF Value™ is $15.15, compared to a current price of $15.75 — trading 4% above its estimated fair value. The current EV-to-EBITDA is 23.81, which is 26% below median its 10-year median of 32.10 and 64.9% above the Medical Devices & Instruments industry median of 14.44. AddLife AB's overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For AddLife AB (ADDLF), the current EV-to-EBITDA is 23.81 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AddLife AB (ADDLF) Overvalued in 2026?
Based on GuruFocus' analysis, AddLife AB stock appears to be overvalued.
The current stock price of $15.75 is trading 4% above its estimated GF Value™ of $15.15.
Key valuation signals for ADDLF:
EV-to-EBITDA: 23.81 (26% below median its 10-year median of 32.10)
GF Value™: $15.15 vs. price of $15.75 (4% above fair value)
Industry Position: 64.9% above the Medical Devices & Instruments median (#377 of 512)
No single metric tells the full story. See the ADDLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddLife AB is engaged in the business of providing products, services, and advisory services. The company operates in two segments: Labtech and Medtech. The Labtech segment provides analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical service to laboratories in medicine, research, academia and the food and pharmaceutical industries. The Medtech segment includes a range that spans from basic consumables to instruments for surgical procedures, welfare technology, and assistive devices for the elderly and disabled. The majority of revenue is derived from the Medtech segment.
88GF Score
Get the complete analysis for ADDLF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADDLF has been successfully added to your 
